Compare MPLT & RQI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPLT | RQI |
|---|---|---|
| Founded | 2018 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2025 | 2001 |
| Metric | MPLT | RQI |
|---|---|---|
| Price | $11.75 | $12.50 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $32.67 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 619.7K |
| Earning Date | 05-28-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.20% |
| EPS Growth | ★ 82.39 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.10 | $11.30 |
| 52 Week High | $40.43 | $13.57 |
| Indicator | MPLT | RQI |
|---|---|---|
| Relative Strength Index (RSI) | 28.18 | 50.04 |
| Support Level | $9.10 | $12.06 |
| Resistance Level | $20.73 | $13.47 |
| Average True Range (ATR) | 1.49 | 0.16 |
| MACD | -0.16 | -0.01 |
| Stochastic Oscillator | 35.72 | 43.36 |
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
COHEN & STEERS QUALITY INCOME REALTY FUND INC is a diversified, closed-end management investment company. The primary investment objective of the fund is high current income through investment in real estate securities. The Fund's secondary objective is capital appreciation. The Fund invests at least its total assets in income-producing common stocks and other securities issued by real estate companies, such as real estate investment trusts under normal market conditions.